Bio-Connect

NPC2 ELISA Kit (Human)

OKCD01269
Aviva Systems Biology
ReactivityHuman
Product group Assays
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Aviva Systems Biology
  • Product Name
    NPC2 ELISA Kit (Human)
  • Delivery Days Customer
    23
  • Application Supplier Note
    Assay Methodology: Quantitative Sandwich Immunoassay
  • Applications
    ELISA
  • Assay Detection Range
    0.78-50ng/mL
  • Assay Sensitivity
    < 0.29 ng/mL
  • Assay Test Principle
    The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Niemann Pick Disease Type C2 (NPC2). Standards or samples are then added to the...
  • Assay Time
    3h
  • Certification
    Research Use Only
  • Scientific Description
    Intracellular cholesterol transporter which acts in concert with NPC1 and plays an important role in the egress of cholesterol from the endosomal/lysosomal compartment. Both NPC1 and NPC2 function as the cellular tag team duo (TTD) to catalyze the mobilization of cholesterol within the multivesicular environment of the late endosome (LE) to effect egress through the limiting bilayer of the LE. NPC2 binds unesterified cholesterol that has been released from LDLs in the lumen of the late endosomes/lysosomes and transfers it to the cholesterol-binding pocket of the N-terminal domain of NPC1. Cholesterol binds to NPC1 with the hydroxyl group buried in the binding pocket and is exported from the limiting membrane of late endosomes/ lysosomes to the ER and plasma membrane by an unknown mechanism. The secreted form of NCP2 regulates biliary cholesterol secretion via stimulation of ABCG5/ABCG8-mediated cholesterol transport.
  • Reactivity
    Human
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    41116100
  • Species
    Human

References

  • Discovery of novel biomarkers for atherosclerotic aortic aneurysm through proteomics-based assessment of disease progression. Yagi H et al., 2020 Apr 14, Sci Rep
    Read this paper